SCHEMBL5492905

SCHEMBL5492905

O=C(NCc1cccnc1)c1ccc2[nH]c3c(c2c1)CCCC3NCCc1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.48
KMT2A Q03164 3/20 0.48
NPC1 O15118 2/20 0.48
GAA P10253 2/20 0.48
MEN1 O00255 2/20 0.48
RAB9A P51151 1/20 0.48
MAPK1 P28482 3/20 0.47
DHODH Q02127 1/20 0.47
MAPK3 P27361 1/20 0.46
MAPT P10636 2/20 0.44
ALOX15 P16050 2/20 0.44
PARP1 P09874 2/20 0.43
CDK1 P06493 1/20 0.43
CDK2 P24941 1/20 0.43
ROCK2 O75116 3/20 0.43
CDC42 P60953 1/20 0.43
CASP6 P55212 1/20 0.42
LMNA P02545 1/20 0.41
GLA P06280 1/20 0.41
SNCA P37840 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459002 0.93 DHODH (0.47) SMN1; SMN2KMT2AGAAMAPK1DHODH
SCHEMBL5454096 0.91 CDC42 (0.50) SMN1; SMN2KMT2ANPC1GAAMEN1
SCHEMBL5460464 0.91 BRD3 (0.44) GAADHODHPARP1CDK1CDK2
SCHEMBL5452942 0.89 NAMPT (0.48) SMN1; SMN2KMT2AGAAMAPK1DHODH
SCHEMBL5456586 0.89 BRD3 (0.45) GAAPARP1CDK1CDK2CDC42
SCHEMBL5461879 0.89 GAA (0.51) SMN1; SMN2KMT2AGAAMAPTPARP1
SCHEMBL5445856 0.88 CDC42 (0.48) KMT2AGAAMEN1DHODHMAPT
SCHEMBL5460537 0.87 CDC42 (0.49) KMT2AGAAMEN1MAPK1DHODH
SCHEMBL5466544 0.86 TRPV1 (0.49) KMT2AGAAMEN1DHODHMAPT
SCHEMBL5459638 0.86 GAA (0.47) SMN1; SMN2KMT2AGAAMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276009-A1 Compositions and Methods for Viral Inhibition MAVS, SARS1, ZC3HAV1 SMN1; SMN2 4824/4885KMT2A 4049/4885NPC1 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.